TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 3, 2008, Pages 268-277

  Kleiner, Yana ^a   Bar Am, Orit ^a   Amit, Tamar ^a   Berdichevski, Alexandra ^a   Liani, Esti ^a   Maor, Gila ^a   Reiter, Irina ^a   Youdim, Moussa B H ^a   Binah, Ofer ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Apoptosis; Cardiotoxicity; Caspase 3; Doxorubicin; Propargylamine; Serum starvation; TVP1022; Ventricular cardiomyocytes

Indexed keywords

CASPASE 3; CYTOCHROME C; DOXORUBICIN; NEUROPROTECTIVE AGENT; PROPARGYLAMINE; PROTEIN BAX; PROTEIN BCL 2; RASAGILINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; DRUG DERIVATIVE; INDAN DERIVATIVE; PARGYLINE; PROPYLAMINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE CELL; HEART PROTECTION; HELA CELL; HUMAN; HUMAN CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; ANIMAL; CELL CULTURE; DRUG EFFECT; FEMALE; HEART DISEASE; HEART VENTRICLE; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; STEREOISOMERISM; TUMOR CELL LINE;

ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARDIOTONIC AGENTS; CASPASE 3; CELL LINE, TUMOR; CELLS, CULTURED; DOXORUBICIN; FEMALE; HEART DISEASES; HEART VENTRICLES; HUMANS; INDANS; MYOCYTES, CARDIAC; PARGYLINE; PROPYLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 58149267992     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181862441     Document Type: Article

References (51)

1. Yaoita H, Ogawa K, Maehara K, et al. Attenuation of ischemia/ reperfusion injury in rats by a caspase inhibitor. Circulation. 1998;97: 276-281.
2. Laugwitz KL, Moretti A, Weig HJ, et al. Blocking caspase-activated apoptosis improves contractility in failing myocardium. Hum Gene Ther. 2001;12:2051-2063.
3. Saraste A, Pulkki K, Kallajoki M, et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest. 1999;29: 369-371.
4. Belzacq AS, Vieira HL, Kroemer G, et al. The adenine nucleotide translocator in apoptosis. Biochimie. 2002;84:167-176.
5. Belzacq AS, Vieira HL, Verrier F, et al. Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res. 2003;63:541-546.
6. Belzacq AS, Brenner C. The adenine nucleotide translocator: a new potential chemotherapeutic target. Curr Drug Targets. 2003;4: 517-524.
7. Friberg H, Wieloch T. Mitochondrial permeability transition in acute neurodegeneration. Biochimie. 2002;84:241-250.
8. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res. 2004;61:372-385.
9. Mattson MP, Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med. 2003;9: 196-205.
10. Pollack M, Phaneuf S, Dirks A, et al. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann N Y Acad Sci. 2002;959:93- 107.
11. Weiss JN, Korge P, Honda HM, et al. Role of the mitochondrial permeability transition in myocardial disease. Circ Res. 2003;93:292-301.
12. Doroshow JH. Anthracyclines and anthracenediones. In: Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd ed. Chabner BA, Longo DLM (eds). Philadelphia: Lippincott Williams and Wilkins; 2001: 500-537.
13. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
14. Bialik S, Cryns VL, Drincic A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res. 1999;85:403-414.
15. Bonavita F, Stefanelli C, Giordano E, et al. H9c2 cardiac myoblasts undergo apoptosis in a model of ischemia consisting of serum deprivation and hypoxia: inhibition by PMA. FEBS Lett. 2003;536:85-91.
16. Umansky SR, Cuenco GM, Khutzian SS, et al. Post-ischemic apoptotic death of rat neonatal cardiomyocytes. Cell Death Differ. 1995;2:235-241.
17. Rubin Y, Kessler-Icekson G, Navon G. The effect of furosemide on calcium ion concentration in myocardial cells. Cell Calcium. 1995;18: 135-139.
18. Chularojmontri L, Wattanapitayakul SK, Herunsalee A, et al. Antiox-idative and cardioprotective effects of Phyllanthus urinaria L. on doxorubicin-induced cardiotoxicity. Biol Pharm Bull. 2005;28: 1165-1171.
19. Olivetti G, Quaini F, Sala R, et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol. 1996;28:2005-2016.
20. Abbate A, Biondi-Zoccai GG, Baldi A. Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling. J Cell Physiol. 2002;193:145-153.
21. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
22. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003;17:2481-2495.
23. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899-1911.
24. Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol. 2002;34:1595-607.
25. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37:837-846.
26. Kalyanaraman B, Joseph J, Kalivendi S, et al. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002;234-235:119-124.
27. Sawyer DB, Fukazawa R, Arstall MA, et al. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res. 1999;84:257-265.
28. Shizukuda Y, Matoba S, Mian OY, et al. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem 2005;273:25-32.
29. Bonavita F, Stefanelli C, Giordano E, et al. H9c2 cardiac myoblasts undergo apoptosis in a model of ischemia consisting of serum deprivation and hypoxia: inhibition by PMA. FEBS Lett. 2003;536:85-91.
30. Umansky SR, Shapiro JP, Cuenco GM, et al. Prevention of rat neonatal cardiomyocyte apoptosis induced by simulated in vitro ischemia and reperfusion. Cell Death Differ. 1997;4:608-616.
31. Xiao-Hong Y, Li L, Yan-Xia P, et al. Salusins protect neonatal rat cardiomyocytes from serum deprivation-induced cell death through upregulation of GRP78. J Cardiovasc Pharmacol. 2006;48:41-46.
32. Zhu H, Elwee-Witmer S, Perrone M, et al. Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced apoptosis. Cell Death Differ. 2000;7:773-784.
33. Bartling B, Milting H, Schumann H, et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation. 1999;100 (19 Suppl):II216-II223.
34. Maulik N, Goswami S, Galang N, et al. Differential regulation of Bcl-2, AP-1 and NF-kappaB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation. FEBS Lett. 1999;443:331-336.
35. Misao J, Hayakawa Y, Ohno M, et al. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation. 1996; 94:1506-1512.
36. Wang L, Ma W, Markovich R, et al. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res. 1998;83: 516-522.
37. Zhu H, Elwee-Witmer S, Perrone M, et al. Phenylephrine protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced apoptosis. Cell Death Differ. 2000;7:773-784.
38. Maruyama W, Akao Y, Youdim MB, et al. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl. 2000;60: 171-186.
39. Weinreb O, Bar-Am O, Amit T, et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18:1471-1473.
40. Mattson MP, Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol Med. 2003;9:196-205.
41. Pollack M, Phaneuf S, Dirks A, et al. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann N Y Acad Sci. 2002; 959:93-107.
42. Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105-108.
43. Yi H, Maruyama W, Akao Y, et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl (R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm. 2006;113:21-32.
44. Weinreb O, Bar-Am O, Amit T, et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18:1471-1473.
45. Kitani K, Minami C, Maruyama W, et al. Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl. J Neural Transm Suppl. 2000;60: 139-156.
46. Weinreb O, Bar-Am O, Amit T, et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18:1471-1473.
47. Yi H, Maruyama W, Akao Y, et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl (R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm. 2006;113:21-32.
48. Youdim MB, Bar AO, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79:172-179.
49. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta. 2002; 1588:94-101.
50. Solem LE, Heller LJ, Wallace KB. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J Mol Cell Cardiol. 1996;28:1023-1032.
51. Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol. 2002;34:1595-607.